3.21
+0.02(+0.63%)
Currency In USD
| Previous Close | 3.19 |
| Open | 3.22 |
| Day High | 3.24 |
| Day Low | 3.11 |
| 52-Week High | 4.02 |
| 52-Week Low | 2.46 |
| Volume | 208,025 |
| Average Volume | 341,982 |
| Market Cap | 254.74M |
| PE | -1.98 |
| EPS | -1.62 |
| Moving Average 50 Days | 3.19 |
| Moving Average 200 Days | 3.16 |
| Change | 0.02 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $105.8 as of October 25, 2025 at a share price of $3.21. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 3 years ago, it would be worth $579.42 as of October 25, 2025 at a share price of $3.21.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals to Host Virtual HCV KOL Panel Event on November 13, 2025
GlobeNewswire Inc.
Oct 22, 2025 11:00 AM GMT
BOSTON, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to
Atea Pharmaceuticals to Present New Data Supporting Combination of Bemnifosbuvir and Ruzasvir as Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025
GlobeNewswire Inc.
Oct 07, 2025 12:00 PM GMT
BOSTON, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, to
Atea Pharmaceuticals to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
GlobeNewswire Inc.
Sep 02, 2025 11:00 AM GMT
BOSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, t